Gwendolyn M. Clay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gwendolyn M. Clay has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Adam Mark
1 shared publicationAlexander Zygmunt
1 shared publicationAnwesha Sanyal
1 shared publication- Barbara Hallinan
Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH , USA Division of Child Neurology, Cincinnati Children's Hospital Medical Center , Cincinnati, OH , USA
1 shared publication Bayan Sudan Zhanbolat
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242
1 shared publication- Blaise V. Jones
Department of Radiology and Medical Imaging Cincinnati Children's Hospital Medical Center and University of Cincinnati Cincinnati Ohio USA
1 shared publication
Latest Publications
- Top Cited Papers
- 15 June 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 388 (24) , 2241-2252
Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome
Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma. The cause is unknown, and mortality is high. We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM. Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 (STAT4). Primary skin fibroblast and cell-line assays were used to define the functional nature of the genetic defect. We also assayed gene expression using single-cell RNA sequencing of peripheral-blood mononuclear cells to identify inflammatory pathways that may be affected in DPM and that may respond to therapy. Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4. In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen matrix, and matrix secretion. Inhibition of Janus kinase (JAK)-STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects. Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition. Gain-of-function variants in STAT4 caused DPM in the families that we studied. The JAK inhibitor ruxolitinib attenuated the dermatologic and inflammatory phenotype in vitro and in the affected family members. (Funded by the American Academy of Allergy, Asthma, and Immunology Foundation and others.).
- 15 June 2023
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 388 (24) , 2241-2252
Top Cited PapersVariant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome
Disabling pansclerotic morphea (DPM) is a rare systemic inflammatory disorder, characterized by poor wound healing, fibrosis, cytopenias, hypogammaglobulinemia, and squamous-cell carcinoma. The cause is unknown, and mortality is high. We evaluated four patients from three unrelated families with an autosomal dominant pattern of inheritance of DPM. Genomic sequencing independently identified three heterozygous variants in a specific region of the gene that encodes signal transducer and activator of transcription 4 (STAT4). Primary skin fibroblast and cell-line assays were used to define the functional nature of the genetic defect. We also assayed gene expression using single-cell RNA sequencing of peripheral-blood mononuclear cells to identify inflammatory pathways that may be affected in DPM and that may respond to therapy. Genome sequencing revealed three novel heterozygous missense gain-of-function variants in STAT4. In vitro, primary skin fibroblasts showed enhanced interleukin-6 secretion, with impaired wound healing, contraction of the collagen matrix, and matrix secretion. Inhibition of Janus kinase (JAK)-STAT signaling with ruxolitinib led to improvement in the hyperinflammatory fibroblast phenotype in vitro and resolution of inflammatory markers and clinical symptoms in treated patients, without adverse effects. Single-cell RNA sequencing revealed expression patterns consistent with an immunodysregulatory phenotype that were appropriately modified through JAK inhibition. Gain-of-function variants in STAT4 caused DPM in the families that we studied. The JAK inhibitor ruxolitinib attenuated the dermatologic and inflammatory phenotype in vitro and in the affected family members. (Funded by the American Academy of Allergy, Asthma, and Immunology Foundation and others.).
- 12 November 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 1-5
Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2
- 12 November 2021
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 1-5
Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2
- Open Access
- 15 October 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199 (8) , 2823-2833
An Anti-Inflammatory Role for NLRP10 in Murine Cutaneous Leishmaniasis
The role of the nucleotide-binding domain and leucine-rich repeat containing receptor NLRP10 in disease is incompletely understood. Using three mouse strains lacking the gene encoding NLRP10, only one of which had a coincidental mutation in DOCK8, we documented a role for NLRP10 as a suppressor of the cutaneous inflammatory response to Leishmania major infection. There was no evidence that the enhanced local inflammation was due to enhanced inflammasome activity. NLRP10/DOCK8-deficient mice harbored lower parasite burdens at the cutaneous site of inoculation compared with wild-type controls, whereas NLRP10-deficient mice and controls had similar parasite loads, suggesting that DOCK8 promotes local growth of parasites in the skin, whereas NLRP10 does not. NLRP10-deficient mice developed vigorous adaptive immune responses, indicating that there was not a global defect in the development of Ag-specific cytokine production. Bone marrow chimeras showed that the anti-inflammatory role of NLRP10 was mediated by NLRP10 expressed in resident cells in the skin rather than by bone marrow–derived cells. These data suggest a novel role for NLRP10 in the resolution of local inflammatory responses during L. major infection.
- 15 October 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 199 (8) , 2823-2833
Open AccessAn Anti-Inflammatory Role for NLRP10 in Murine Cutaneous Leishmaniasis
The role of the nucleotide-binding domain and leucine-rich repeat containing receptor NLRP10 in disease is incompletely understood. Using three mouse strains lacking the gene encoding NLRP10, only one of which had a coincidental mutation in DOCK8, we documented a role for NLRP10 as a suppressor of the cutaneous inflammatory response to Leishmania major infection. There was no evidence that the enhanced local inflammation was due to enhanced inflammasome activity. NLRP10/DOCK8-deficient mice harbored lower parasite burdens at the cutaneous site of inoculation compared with wild-type controls, whereas NLRP10-deficient mice and controls had similar parasite loads, suggesting that DOCK8 promotes local growth of parasites in the skin, whereas NLRP10 does not. NLRP10-deficient mice developed vigorous adaptive immune responses, indicating that there was not a global defect in the development of Ag-specific cytokine production. Bone marrow chimeras showed that the anti-inflammatory role of NLRP10 was mediated by NLRP10 expressed in resident cells in the skin rather than by bone marrow–derived cells. These data suggest a novel role for NLRP10 in the resolution of local inflammatory responses during L. major infection.